Abstract. Epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases (RTKs) are overexpressed and/or mutated in various cancers and their abnormal activation is implicated in carcinogenesis. We explored the possibility of generating an imaging probe for RTK activation using the SH2 domain of Grb2 for cancer characterization. For cell penetration, molecular analysis and radiolabeling, the SH2 domain was fused with TAT, flag and tyrosine residue, respectively (termed TSF). We analyzed TSF characteristics in cells such as cellular uptake, stability and localization. After uptake into EGFR-expressing cells, TSF was found to be binding to phosphorylated-EGFR, which increased by stimulation with EGF. TSF was co-localized with EGFR in EGFR-activated cells, while it was localized as dots in cytosol in EGFR-non-activated cells. Cellular retention time of TSF was significantly extended under EGFR activation with EGF stimuli and reduced under the treatment with a tyrosine kinase inhibitor, Tyrphostin AG1478. In conclusion, the SH2 domain of Grb2 has the potential to be used as a binding component of a probe to detect activated-RTK and to evaluate the effect of kinase inhibitors on RTK activation.
Introduction
Receptor tyrosine kinase (RTK) consists of an extracellular ligand binding domain, a transmembrane domain and an intracellular domain, and is activated by binding with its ligands, typically growth factors. When the ligand binds with its receptor, it induces autophosphorylation of tyrosine (Tyr) residues on the intracellular carboxyl terminal tail of the receptor (1, 2) . Activated-RTKs can associate with several adaptor proteins containing Src-homology 2 (SH2) domain, such as growth factor receptor bound protein 2 (Grb2), Src homologous and collagen (Shc), and phospholipase C Á (PLCÁ). The SH2 domain consists of ~100 amino acids and binds to phosphorylated-Tyr of RTKs. The binding leads to the promotion of cell signaling through several pathways to regulate cellular physiology such as cell growth, survival, motility, angiogenesis and differentiation (3) (4) (5) (6) .
As upregulated expression and activation of RTKs are commonly found in cancers and tightly related to their characteristics (7) , RTKs are very attractive targets for cancer diagnosis and therapy (8) . There have been various approaches to target RTKs, such as using their ligands, anti-RTK antibodies, and specific Tyr kinase inhibitor (9) (10) (11) (12) (13) (14) (15) (16) . Most of them target the earlier part of the signaling pathway, that is, from ligand binding to Tyr phosphorylation. However, in some cancers, RTK is known to be mutated or have lost the extracellular ligand binding domain but is activated (7, 14, 15, (17) (18) (19) (20) . In such cases, the later part of the signaling pathway, that is, from the binding of adaptor proteins to RTKs via the SH2 domain and thereafter, can provide a desirable target.
In this study, we focused on the SH2 domain of Grb2 as a key component for designing an imaging probe that would allow the detection of RTK activation. Grb2 is ~25 kDa protein consisting of one SH2 domain flanked by two SH3 domains (21) , and intermediates the mitogen-activated protein kinase (MAPK) signaling pathway and also regulates receptor trafficking (22) (23) (24) . Grb2 works with various RTKs, with epidermal growth factor receptor (EGFR) being its major binding partner (4, 25) . EGFR, which regulates many cell functions ( Fig. 1) , is overexpressed and/or mutated in various cancers including breast cancer, head and neck cancer, ovarian cancer and non-small cell lung carcinoma, and has been implicated in the pathogenesis of the disease (16, 19, 20) . In addition, there has been no mutation reported in RTK at the binding sites for the SH2 domain of Grb2.
Based on these considerations, we designed a protein probe consisting of the SH2 domain of Grb2, HIV-TAT for protein delivery, flag for molecular tag and Tyr residue for radiolabeling. We investigated the characteristics of the probe in cells with different activation level of EGFR, as a representative of RTKs, in order to evaluate the possibility to use the probe for in vivo imaging of RTK activation.
Materials and methods
Cell culture. Human skin cancer A431 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and breast cancer MDA-MB435 cells and lung cancer H3255 cells were kindly provided by Dr R. Nishii of Shiga Medical Center. A431 cells were cultured in Dulbecco's modified Eagle medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) containing 10% fetal bovine serum (FBS, SAFC Biosciences, Lenexa, KS, USA), 50 U/ml of penicillin and 50 μg/ml of streptomycin (Gibco Invitrogen Corp., Carlsbad, CA, USA) in a humidified atmosphere of 5% CO 2 in air at 37˚C. MDA-MB435 cells and H3255 cells were cultured in DMEM/F-12 (Sigma-Aldrich), containing 10% FBS and antibiotics as above.
Plasmids. Grb2 cDNA clone (accession no: NM_203506) was obtained from NIH Mammalian Gene Collection (Invitrogen). The cDNA fragment encoding the SH2 domain fused with TAT was amplified by PCR using a forward primer (5'-ATG TAT GGC AGG AAG AAG CGG AGA CAG CGA CGA AGA GGT GAA ATG AAA CCA CAT CCG TGG-3') and a reverse primer (5'-AAA GAG GGC CTG GAC GTA TGT CGG CTG-3'). Then, for fusion of flag with Tyr sequence, the obtained fragments were amplified by PCR using a forward primer (5'-ATG TAT GGC AGG AAG AAG CG-3') and a reverse primer (5'-TTA GTA CTT ATC GTC GTC ATC CTT GTA ATC GGG CCC AAA GAG GGC CTG G-3'). We also amplified a fragment for control protein without TAT sequence, using a forward primer (5'-ATG GAA ATG AAA CCA CAT CCG TGG-3') and the above reverse primer. To add the matching restriction sites with pGEX-6P-1 or pGEX-6P-3 vector (GE Healthcare, Uppsala, Sweden), the fragment was amplified using a forward primer (5'-CCC TGG AGA ATT CAT GTA TGG CAG GAA GAA G-3') or (5'-GAC GGC TTC ATT CCC AAG AAT TCC ATG GAA ATG AAA CCA C-3') and a reverse primer (5'-GCT TAC CGC GGC CGC TTA GTA CTT ATC GTC GTC-3'). The fragments were inserted between EcoRI and NotI sites of the vectors using Ligation High (Toyobo Co., Ltd., Osaka, Japan) to obtain pGEX-TSF and pGEX-SF to express the probe proteins, the SH2 domain fused with TAT, flag and Tyr (TSF), and the SH2 domain fused with flag and Tyr (SF), respectively.
All constructs were transformed into E. coli DH5· (Toyobo) and subsequently screened by restriction analysis, and their DNA sequences were read with ABI PRISM 3100 sequencer (Applied Biosystems, Foster City, CA, USA).
Probe preparation. The GST fusion constructs pGEX-TSF and pGEX-SF were transformed into E. coli BL21 and cultured in Overnight Express Instant TB Medium (Novagen, Darmstadt, Germany) to express GST fusion proteins. Recombinant GST fusion proteins were purified using MicroSpin GST purification module or GSTrap FF. Then, the proteins were digested by PreScission Protease following the manufacturer's instructions. Columns and protease were purchased from GE Healthcare.
Probe labeling with
125 I. 125 I-labeled protein was prepared by chloramine-T-mediated iodination. Protein (1 μg) was mixed with 3.7 MBq of Na[
125 I] (Perkin Elmer Japan Co., Ltd., Kanagawa, Japan) in 0.3 M phosphate buffer (pH 7.5) for 2 min at room temperature (RT). Chloramine-T (1 μl of 4 mg/ ml) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) was added to 28 μl of the protein mixture and incubated for 5 min at RT, and the reaction was terminated by adding 6 μl of 0.19 mg/ml sodium metabisulfite (Nacalai Tesque, Kyoto, Japan). The labeled protein was separated from free iodine by gel filteration using a PD10 column (GE Healthcare) equilibrated with 0.1 M acetate buffer (pH 6.0) containing 1% bovine serum albumin (Sigma). The labeling efficiency was ~76.8±6.84% and an average of 0.8 molecule of 125 I was calculated to be on one TSF molecule. Column purification resulted in radiochemical purity of >99%.
Antibodies. Anti-EGFR (R-1), anti-EGFR (1005), and antiactin (C-11) antibodies, donkey anti-goat IgG conjugated with horseradish peroxidase (HRP), and goat anti-mouse IgG conjugated with HRP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Goat anti-rabbit IgG conjugated with HRP was purchased from GE Healthcare. Mouse anti-flag M2 and rabbit anti-flag polyclonal antibodies were from Sigma. Anti-phospho-EGFR (Tyr 1068 ) antibody was from Cell Signaling Technology (Beverly, MA, USA). Goat anti-rabbit IgG conjugated with Alexa Flour 488 and goat antimouse IgG conjugated with Alexa Flour 594 were purchased from Invitrogen.
Western blotting. Cell lysates containing 15-20 μg protein or immunoprecipitation samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membrane (Millipore, Billerica, MA, USA). They were then probed with primary antibodies. HRP-conjugated secondary antibodies were detected using chemiluminescence with ECL Plus Western blotting detection system (GE Healthcare). Bands were visualized by Chemi-Smart 5000 (Vilber Lourmat, Torcy, France) and Chemi-Capt software (Vilber Lourmat). Band intensity was quantified by Image J software (National Institutes of Health, Bethesda, MD, USA).
Immunoprecipitation. Immunoprecipitation was performed by FLAG Tagged protein immunoprecipitation kit (Sigma). Briefly, total cell lysates containing ~1 mg protein were incubated with washed beads conjugated with anti-flag antibody at 4˚C overnight. The protein was eluted by 3X FLAG peptide according to the manufacturer's instructions.
Immunofluorescence staining. Cells were cultured on glass cover slips (Matsunami, Osaka, Japan) and fixed in 4% paraformaldehyde (Wako) for 20 min at RT. The cells were then permeabilized with 0.1% Triton X-100 (Promega KK, Tokyo, Japan) in PBS for 2 min at RT and blocked in 5% normal goat serum (Sigma) in Blockase (DS Pharma Biomedical, Osaka, Japan) for 30 min at RT. After the blocking, the cells were incubated with primary antibodies overnight at 4˚C, washed with 0.1% Tween (Sigma) in PBS (PBST), and then incubated with fluorescence-labeled secondary antibodies for 2-3 h at RT. After the PBST and PBS washes, the cover slips were mounted with Aqua-Poly/Mount Coverslipping Medium (Polysciences Inc., Warrington, PA, USA). The slides were examined with a confocal fluorescence microscope, FV1000 (Olympus, Tokyo, Japan).
Transduction into cells. For comparison of probe transduction into A431 cells and MDA-MB435 cells, the cells at 4.0x10
5 cells/well in 24-well plates were incubated with 1.5 μM TSF for 1.5 h. After washing the cells with PBS and 0.2 M glycine-HCl buffer (pH 2.0) to remove probes on the cell surface, cell lysates were prepared for Western blotting. The band intensity detected by anti-flag antibody was normalized to actin.
The transduction was also examined with 125 I-labeled TSF ( 125 I-TSF). The cells at 4.0x10 5 cells/well in 24-well plates were incubated with 1.5 kBq 125 I-TSF for 1.5 h. After washing, the cells were collected and their radioactivity was measured by Á-counter (Aloka Co., Ltd., Tokyo, Japan).
Probe binding to EGFR. For assessment of the binding of TSF and phosphorylated-EGFR, A431 cells at 3.0x10 6 cells in 100-mm dish were pre-incubated in serum-free media for 24 h, and then treated with 1.5 μM TSF or SF in serum-free medium for 1.5 h. EGF at a final concentration of 100 ng/ml was added to the medium for the last 10 min of incubation. Cell lysates were prepared for immunoprecipitation to detect TSF-EGFR complex by Western blotting.
Probe retention under EGFR activation. For assessment of the effect of EGFR activation on TSF retention, 4.0x10 5 of serum-starved A431 cells in 24-well plates were incubated with 1.5 μM TSF or 1.5 kBq of 125 I-TSF for 1.5 h. After washing, the cells were cultured in serum-free medium with or without 100 ng/ml EGF for 0, 10, 30, or 60 min. Cell lysates were prepared at each time point for Western blotting or for the measurement of radioactivity by Á-counter.
Intracellular localization of the probe under EGFR activation.
A431 cells on glass cover slips were cultured in serum-free medium for 24 h, and 1.5 μM TSF was added to the cells for 1.5 h. After washing, 100 ng/ml EGF was added for 10 min. Immunofluorescence staining against TSF and EGFR was performed as described in 'Immunofluorescence staining' using anti-flag and anti-EGFR antibodies as primary antibodies, respectively.
Intracellular localization of the probe and lysosome. A431 cells and MDA-MB435 cells were cultured in serum-added medium on glass cover slips and treated with 1.5 μM TSF and 50 μM LysoTracker Red (Invitrogen) for 1.5 h. Immunofluorescence staining was performed as described in 'Immunofluorescence staining' to detect TSF and lysosomes. 5 cells/well in 24-well plates were incubated with 1.5 μM TSF for 1.5 h in medium containing FBS. After washing, the medium was replaced by the medium without TSF, and the cells were cultured for 30 min. Before and after the 30 min TSF-free incubation, cell lysates were prepared for Western blotting. The band intensity detected by anti-flag antibody was normalized to actin.
Probe retention under treatment with Tyr kinase inhibitor.
H3255 cells were cultured at 1.0x10 5 cells/well in 24-well plates. Medium was changed to serum-free one and cultured for 48 h. Cells were then incubated with 1.5 μM TSF with or without 10 μM Tyrphostin AG1478 (Sigma), a highly selective EGFR inhibitor, for 1.5 h. After washing, cells were stimulated with 100 ng/ml EGF for 10 min. Cell lysates were prepared for Western blotting. Samples immediately after incubation with TSF, with or without AG1478 treatment, were used as control to evaluate the amount of the intact probe.
Statistical analysis. Aspin-Welch's t-test or Student's t-test was used, depending on the results of F-test.
Results
Confirmation of purified proteins. For protein delivery into cells, we fused TAT at the N termini of the SH2 domain. At C termini, flag tag and Tyr residue were fused for molecular analysis and radiolabeling, respectively (Fig. 2A) . The purified probe proteins, TSF and its TAT-deficient control, termed SF, were identified by SDS-PAGE. Each protein appeared as a single band at the expected molecular weight; TSF was detected at 16 kDa and SF at 14 kDa (Fig. 2B) .
TSF uptake and binding to EGFR.
When the probe proteins were incubated with cells in culture, TSF, but not SF, was found in the cells, confirming that the conjugation of TAT enabled the SH2 domain to be delivered into cells (Fig. 3A) . We compared TSF uptake into the cells expressing different amount of EGFR, A431 cells overexpressing EGFR and MDA-MB435 cells expressing an undetectable amount of EGFR, by Western blotting. TSF was taken up into both cells, with the amount not significantly different between the two (Fig. 3A) . We also compared the transduction efficiency by incubation with 125 I-TSF and measurement of its radioactivity, and there was no significant difference between the two; it was 24.6±2.11% in A431 cells and 20.4±0.88% in MDA-MB435 cells (Fig. 3B) .
Immunoprecipitation assay confirmed that our probe could bind to phosphorylated-EGFR after the penetration into cells (Fig. 3C) . In the absence of EGF, only small amount of phosphorylated-EGFR was found to be binding to TSF. EGF treatment resulted in marked increase in the binding of TSF and phosphorylated-EGFR.
Effect of EGFR activation on TSF retention.
To assess whether TSF retention was dependent on EGFR activation, A431 cells cultured in serum-free medium to suppress EGFR activation were treated with TSF for 1.5 h. After the removal of TSF, the cells were cultured in EGF-containing medium to promote EGFR activation. During the first 10 min of EGF treatment, the TSF amount only decreased to 65%, while it rapidly decreased to 37% in untreated cells. The initial half-life, during which the amount of intact TSF decreased to 50%, was 42 min in EGF-treated cells, while it was 7.2 min in untreated cells (Fig. 4A) . The TSF retention was also evaluated with 125 I-TSF (Fig. 4B) . The radioactivity in EGFR-activated cells after the removal of 125 I-TSF tented to be higher than that in non-activated cells during the period of experiment. Fig. 5 shows the immunofluorescence staining examining the TSF distribution in A431 cells under EGFR activation. TSF co-localized with EGFR near the cell membrane in EGFRactivated cells. On the other hand, it was localized as dots in cytosol in EGFR-non-activated cells, and the fluorescence intensity of TSF was seemed to be lower than that in EGFRactivated cells.
Effect of EGFR activation on TSF localization in cells.

Comparison of intracellular localization of TSF, lysosome and TSF retention.
Since TSF seemed to be susceptible to protein degradation in Western blotting study, we examined the subcellular localization of TSF with lysosomes where endocytosed proteins are known to be degraded (Fig. 6A) . In A431 cells, some TSF was co-localized with lysosomes, but most was found near the cell membrane, and did not overlap with lysosomes. On the other hand, in MDA-MB435 cells, TSF and lysosomes were mostly co-localized as dots in cytosol. When comparing the intact TSF remaining in cells at 30 min after the removal of TSF, the amount of TSF in MDA-MB435 cells was significantly less than that in A431 cells (Fig. 6B) .
Effect of Tyr kinase inhibitor on TSF retention.
We also examined the TSF retention under EGFR inactivation by treatment with a chemical inhibitor (Fig. 7) . H3255 cells are known to overexpress EGFR with L858R mutation and be sensitive to Tyr kinase inhibitors. In H3255 cells, EGFR was phosphorylated even in the absence of any added growth factor and when the cells were treated with AG1478, a specific EGFR inhibitor, the phosphorylated-Tyr 1068 of EGFR was decreased regardless of EGF treatment. The transduction efficiency was not affected by AG1478 treatment. At 10 min after the removal of TSF from medium, TSF amount in 
Discussion
There have been studies proposing the utilization of the SH2 domain of the binding partners of membrane RTKs for treatment of cancer through inhibition of signal transduction, imaging and determination of its function (13, 26) . In the present study, we designed a novel molecular probe containing the SH2 domain of Grb2 and examined its properties in cells to assess the possibility of its future use for in vivo imaging of RTK activation, selecting EGFR as its target molecule for the first step. We envisaged that the signal activation would be detected by the different probe retention in cells with presence or absence of phosphorylated-RTK. For protein transduction into cells, we selected HIV-TAT sequence. TAT is one of the cell-penetrating peptides (CPPs) and can deliver protein of >120 kDa into living cells and mouse tissues (11, 27) . It is also reported that protein delivery by TAT is less cytotoxic than that of other CPPs such as polyarginine and transportan (12, 28) . Our probe, TSF, was transduced into cells with both high and low EGFR expression with similar efficiency. This seemed reasonable, as protein transduction by CPP is mostly dependent on the characteristics of the cell membrane and cell surface area for attachment, and the early uptake stage could depend on the characteristics of CPP and not on the expression or activation of EGFR.
To distinguish the cells with different levels of RTK activation by protein probe accumulation, it is necessary to understand and exploit protein metabolism or trafficking after its penetration into the cells. Our probe was unstable in cells and intact probe protein was decreased to ~40% in 1 h even in EGFR-activated cells. Fischer et al reported that TAT labeled with fluorescence showed much lower uptake into cells than other CPPs such as polyarginine and antennapedia because TAT fusion protein was susceptible to intracellular protease and quickly exited from cells (29) . This study supports the concept that TSF instability might be due to TAT characteristics.
In this study, extended retention of TSF was observed in EGFR-activation study. In our preliminary experiment, EGFR was highly phosphorylated at 10-30 min after EGF stimulation, matching the time frame when the extended retention was observed. Furthermore, treatment with EGFR kinase inhibitor resulted in the decrease of Tyr 1068 phosphorylation and shortened TSF retention. Combined with the results of immunoprecipitation and immunofluorescence staining experiments, it could be assumed that EGFR activation could stabilize TSF by an increase in the binding with phosphorylated-EGFR located at the cell membrane. Although the TAT transduction mechanism is still controversial (30, 31) , TAT fusion protein is thought to penetrate into cells in a charge-dependent manner and be brought into endosome (32) . When A431 cells under the normal culture condition were incubated with TSF and lysosome marker, most of TSF showed different distribution from lysosome while they were co-localized in MDA-MB435 cells, which showed shorter retention of TSF than in A431 cells. This also indicates that the stabilization of TSF would be due to the evacuation from protein degradation.
In this study, flag tag was used for most of the experiments to understand and evaluate the basic characteristics of the probe. For in vivo imaging, the probe should be labeled with a 'beacon' detectable from outside of living cells or bodies. Fluorescent dyes would be suitable for imaging at cellular level and radioisotopes for PET (positron emission tomography) or SPECT (single photon emission computed tomography) imaging at whole-body level. Cellular retention of 125 I-TSF, as observed by radioactivity, was higher in EGFRactivated cells than in control cells, suggesting the possibility that radio-iodinated TSF can capture the EGFR activation. 125 I-labeling can be easily replaced by 124 I-labeling. 124 I is a positron emitter widely used for PET imaging both in animal and human studies (33, 34) . However, the less prominent difference between EGFR-activated cells and non-activated cells observed by radioactivity than by Western blotting, which might be attributable to partially degraded TSF with radiolabel, indicates that more suitable labeling methods and radionuclides should be explored.
As Grb2 also binds to phosphorylated-Tyr containing sequences of RTKs other than EGFR, it is likely that TSF would also be able to bind to those phosphorylated-receptors and the behavior of TSF, such as cellular retention and localization, would be influenced by the activation of those receptors. The importance of Grb2 signaling in cell cycle progression and cell motility is now increasingly recognized (35) . Although only the activation of EGFR was examined in this study, it would be interesting to explore the possibility to capture the activation of other signaling pathways going through Grb2 using TSF.
In conclusion, we showed that the stability of the SH2 domain of Grb2 was dependent on the cellular level of EGFR activation in EGFR expressing cells. We hypothesized the trafficking of our probe as follows: TSF could leave endosome relatively quickly into cytosol and bind to phosphorylated-EGFR; if there is no binding partner, TSF will be degraded by proteases in cytosol or in lysosome. Our probe still requires improvements, however, the SH2 domain of Grb2 can be used as a binding component of molecular probes for detecting activated-RTK in cancer and also for evaluating the effect of kinase inhibitors on RTK activation.
